卡铂加依托泊苷与拓扑替康作为敏感复发性小

北京治白癜风专科医院 http://www.baidianfeng51.cn/baidianfengzixun/wuliliaofa/294.html

SCI

30September

Carboplatinplusetoposideversustopotecanassecond-linetreatmentforpatientswithsensitiverelapsedsmall-celllungcancer:anopen-label,multicentre,randomised,phase3trial

BaizeNathalie,MonnetIsabelle,GreillierLaurentetal.Carboplatinplusetoposideversustopotecanassecond-linetreatmentforpatientswithsensitiverelapsedsmall-celllungcancer:anopen-label,multicentre,randomised,phase3trial.[J].LancetOncol.,,21:-.

Background背景

TopotecaniscurrentlytheonlydrugapprovedinEuropeinasecond-linesettingforthetreatmentofsmall-celllungcancer.Thisstudyinvestigatedwhetherthedoubletofcarboplatinplusetoposidewassuperiortotopotecanasasecond-linetreatmentinpatientswithsensitiverelapsedsmall-celllungcancer.

拓扑替康目前是欧洲批准的治疗小细胞肺癌的唯一二线药物。这项研究调查了卡铂联合依托泊苷作为敏感复发性小细胞肺癌患者的二线治疗方案是否优于拓扑替康。

Methods方法

Inthisopen-label,randomised,phase3trialdonein38hospitalsinFrance,weenrolledpatientswithhistologicallyorcytologicallyconfirmedadvancedstageIVorlocallyrelapsedsmall-celllungcancer,whorespondedtofirst-lineplatinumplusetoposidetreatment,butwhohaddiseaserelapseorprogressionatleast90daysafter